These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 19505770)

  • 1. Therapeutic potential of lipase inhibitor orlistat in Alzheimer's disease.
    Du J; Wang Z
    Med Hypotheses; 2009 Nov; 73(5):662-3. PubMed ID: 19505770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
    Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z
    Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orlistat inhibits dietary cholesterol absorption.
    Mittendorfer B; Ostlund RE; Patterson BW; Klein S
    Obes Res; 2001 Oct; 9(10):599-604. PubMed ID: 11595776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A gastrointestinal lipase inhibitor reduces progression of atherosclerosis in mice fed a western-type diet.
    Ueshima K; Akihisa-Umeno H; Nagayoshi A; Takakura S; Matsuo M; Mutoh S
    Eur J Pharmacol; 2004 Oct; 501(1-3):137-42. PubMed ID: 15464072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The community management of chylous fistula using a pancreatic lipase inhibitor (orlistat).
    Belloso A; Saravanan K; de Carpentier J
    Laryngoscope; 2006 Oct; 116(10):1934-5. PubMed ID: 17003701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orlistat reduces gallbladder emptying by inhibition of CCK release in response to a test meal.
    Ellrichmann M; Ritter PR; Otte JM; Schrader H; Banasch M; Brunke G; Herzig KH; Seebeck J; Schmidt WE; Schmitz F
    Regul Pept; 2007 Mar; 139(1-3):136-40. PubMed ID: 17175037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant A beta in plasma.
    Burgess BL; McIsaac SA; Naus KE; Chan JY; Tansley GH; Yang J; Miao F; Ross CJ; van Eck M; Hayden MR; van Nostrand W; St George-Hyslop P; Westaway D; Wellington CL
    Neurobiol Dis; 2006 Oct; 24(1):114-27. PubMed ID: 16899370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia.
    Tonstad S; Pometta D; Erkelens DW; Ose L; Moccetti T; Schouten JA; Golay A; Reitsma J; Del Bufalo A; Pasotti E
    Eur J Clin Pharmacol; 1994; 46(5):405-10. PubMed ID: 7957533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The long-term influence of orlistat on dietary intake in obese subjects with components of metabolic syndrome.
    Svendsen M; Helgeland M; Tonstad S
    J Hum Nutr Diet; 2009 Feb; 22(1):55-63. PubMed ID: 19192027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orlistat, a new lipase inhibitor for the management of obesity.
    Heck AM; Yanovski JA; Calis KA
    Pharmacotherapy; 2000 Mar; 20(3):270-9. PubMed ID: 10730683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mode of action of orlistat.
    Guerciolini R
    Int J Obes Relat Metab Disord; 1997 Jun; 21 Suppl 3():S12-23. PubMed ID: 9225172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipase inhibition attenuates the acute inhibitory effects of oral fat on food intake in healthy subjects.
    O'Donovan D; Feinle-Bisset C; Wishart J; Horowitz M
    Br J Nutr; 2003 Nov; 90(5):849-52. PubMed ID: 14667178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesterol lowering effect of dietary weight loss and orlistat treatment--efficacy and limitations.
    Erdmann J; Lippl F; Klose G; Schusdziarra V
    Aliment Pharmacol Ther; 2004 Jun; 19(11):1173-9. PubMed ID: 15153170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor.
    Singh A; Sarkar SR; Gaber LW; Perazella MA
    Am J Kidney Dis; 2007 Jan; 49(1):153-7. PubMed ID: 17185156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipases and lipolysis in the human digestive tract: where do we stand?
    Armand M
    Curr Opin Clin Nutr Metab Care; 2007 Mar; 10(2):156-64. PubMed ID: 17285003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic and Natural Lipase Inhibitors.
    Bialecka-Florjanczyk E; Fabiszewska AU; Krzyczkowska J; Kurylowicz A
    Mini Rev Med Chem; 2018; 18(8):672-683. PubMed ID: 27484624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orlistat for obesity.
    Med Lett Drugs Ther; 1999 Jun; 41(1055):55-6. PubMed ID: 10436767
    [No Abstract]   [Full Text] [Related]  

  • 18. First clinical studies with orlistat: a short review.
    Drent ML; van der Veen EA
    Obes Res; 1995 Nov; 3 Suppl 4():623S-625S. PubMed ID: 8697067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss.
    Trouillot TE; Pace DG; McKinley C; Cockey L; Zhi J; Häeussler J; Guerciolini R; Showalter R; Everson GT
    Am J Gastroenterol; 2001 Jun; 96(6):1888-94. PubMed ID: 11421247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.